George W. Sledge, Jr, MD | Authors



Heterogeneity and Cancer

September 15, 2014

Cancer heterogeneity, long recognized as an important clinical determinant of patient outcomes, was poorly understood at a molecular level. Genomic studies have significantly improved our understanding of heterogeneity, and have pointed to ways in which heterogeneity might be understood and defeated for therapeutic effect.

TCGA's Breast Cancer Project May Yield Important Therapeutic Benefits, but It's Too Early to Be Sure

December 15, 2013

The strongest aspect of TCGA is that the data are publically available, fueling the input needed for unparalleled discovery. As the broader scientific community continues to analyze and integrate TCGA data with their own datasets, it is highly likely that breast cancer patients will benefit.

The New Millennium for Adjuvant Therapy in Breast Cancer

May 01, 2008

The treatment of microscopic metastatic breast cancer with adjuvant systemic therapy has undergone significant changes in recent years. At the same time, our understanding of the biology of breast cancer has also improved, predominantly as a consequence of data obtained from cDNA microarrays.